• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
The influence of phytotherapy on macroprolactinoma size.植物疗法对大泌乳素瘤大小的影响。
Afr J Tradit Complement Altern Med. 2011 Dec 29;9(2):277-86. doi: 10.4314/ajtcam.v9i2.15. eCollection 2012.
2
The influence of phytotherapy on prolactin level in macroprolactinoma patients.植物疗法对大泌乳素瘤患者催乳素水平的影响。
Afr J Tradit Complement Altern Med. 2011 Oct 2;9(1):67-72. doi: 10.4314/ajtcam.v9i1.10. eCollection 2012.
3
The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas.两种选择性2型多巴胺受体激动剂喹高利特和卡麦角林在治疗泌乳素瘤中的作用。
Clin Endocrinol (Oxf). 2000 Jul;53(1):53-60. doi: 10.1046/j.1365-2265.2000.01016.x.
4
Recurrence of hyperprolactinaemia following discontinuation of dopamine agonist therapy in patients with prolactinoma occurs commonly especially in macroprolactinoma.催乳素瘤患者停用多巴胺激动剂治疗后催乳素血症复发很常见,尤其是在大腺瘤患者中。
Clin Endocrinol (Oxf). 2011 Dec;75(6):819-24. doi: 10.1111/j.1365-2265.2011.04136.x.
5
Diagnosis and drug therapy of prolactinoma.泌乳素瘤的诊断与药物治疗
Drugs. 1996 Jun;51(6):954-65. doi: 10.2165/00003495-199651060-00004.
6
Treatment of macroprolactinoma with cabergoline: a study of 85 patients.卡麦角林治疗大泌乳素瘤:85例患者的研究
Clin Endocrinol (Oxf). 1997 Apr;46(4):409-13. doi: 10.1046/j.1365-2265.1997.1300952.x.
7
Growth hormone secretion elicited by GHRH, GHRP-6 or GHRH plus GHRP-6 in patients with microprolactinoma and macroprolactinoma before and after bromocriptine therapy.在溴隐亭治疗前后,生长激素释放激素(GHRH)、生长激素释放肽-6(GHRP-6)或GHRH加GHRP-6对微泌乳素瘤和大泌乳素瘤患者生长激素分泌的影响。
Clin Endocrinol (Oxf). 1998 Jan;48(1):103-8. doi: 10.1046/j.1365-2265.1998.00360.x.
8
Secondary deterioration of visual field during cabergoline treatment for macroprolactinoma.卡麦角林治疗大泌乳素瘤期间视野的继发性恶化
Clin Endocrinol (Oxf). 2009 Apr;70(4):588-92. doi: 10.1111/j.1365-2265.2008.03364.x. Epub 2008 Jul 31.
9
Large macroprolactinoma treated with bromocriptine alone.仅用溴隐亭治疗的大型泌乳素大腺瘤。
Ann Acad Med Singap. 1996 Nov;25(6):886-9.
10
Recovery of growth hormone secretion following cabergoline treatment of macroprolactinomas.卡麦角林治疗大泌乳素瘤后生长激素分泌的恢复
Clin Endocrinol (Oxf). 2000 Nov;53(5):595-9. doi: 10.1046/j.1365-2265.2000.01137.x.

引用本文的文献

1
Treatment of glioblastoma with herbal medicines.中草药治疗脑胶质母细胞瘤。
World J Surg Oncol. 2018 Feb 13;16(1):28. doi: 10.1186/s12957-018-1329-2.
2
TREATMENT OF PROGRESSION OF DIFFUSE ASTROCYTOMA BY HERBAL MEDICINE: CASE REPORT.中药治疗弥漫性星形细胞瘤进展:病例报告
Afr J Tradit Complement Altern Med. 2016 Sep 29;13(6):1-4. doi: 10.21010/ajtcam.v13i6.1. eCollection 2016.

本文引用的文献

1
The influence of phytotherapy on prolactin level in macroprolactinoma patients.植物疗法对大泌乳素瘤患者催乳素水平的影响。
Afr J Tradit Complement Altern Med. 2011 Oct 2;9(1):67-72. doi: 10.4314/ajtcam.v9i1.10. eCollection 2012.
2
Selective serotonin reuptake inhibitors.选择性5-羟色胺再摄取抑制剂
BMJ. 2004 Oct 9;329(7470):809-10. doi: 10.1136/bmj.329.7470.809.
3
[Clinical and therapeutic aspects of prolactinoma in men].[男性泌乳素瘤的临床与治疗方面]
Arq Neuropsiquiatr. 2003 Dec;61(4):1004-10. doi: 10.1590/s0004-282x2003000600022. Epub 2004 Jan 6.
4
Hyperprolactinemia: etiology, diagnosis, and management.高催乳素血症:病因、诊断与管理
Semin Reprod Med. 2002 Nov;20(4):365-74. doi: 10.1055/s-2002-36709.
5
The pathogenesis of pituitary adenomas.
Clin Endocrinol (Oxf). 1993 Jun;38(6):559-70. doi: 10.1111/j.1365-2265.1993.tb02136.x.
6
Plurihormonal pituitary adenomas.多激素垂体腺瘤
Semin Diagn Pathol. 1986 Feb;3(1):69-82.
7
Ultrastructural diagnosis of human pituitary adenomas.人类垂体腺瘤的超微结构诊断
Microsc Res Tech. 1992 Jan 15;20(2):107-35. doi: 10.1002/jemt.1070200202.

植物疗法对大泌乳素瘤大小的影响。

The influence of phytotherapy on macroprolactinoma size.

作者信息

Trogrlić Ivo, Trogrlić Dragan, Trogrlić Zoran

机构信息

"DREN" Ltd, Žepče, Bosnia & Herzegovina.

出版信息

Afr J Tradit Complement Altern Med. 2011 Dec 29;9(2):277-86. doi: 10.4314/ajtcam.v9i2.15. eCollection 2012.

DOI:10.4314/ajtcam.v9i2.15
PMID:23983347
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3746621/
Abstract

The study aims at demonstrating the efficiency of phytotherapy in macroprolactinoma downsizing. The comparison of phytotherapeutic (PT) efficiency leant on medical records submitted by the patients prior to the PT launch, indicating the diagnosis established based on the outcome of the nuclear magnetic resonance imaging (NMRI) and/or computed tomography (CT) of the affected site and bringing the results of field-of-vision examination and hormonal status determination. The insight into the documentation in reference provided the information on tumour size and prolactin levels. The data in reference were compared against medical records submitted following phytotherapy completion. This study brings the results of a five-year investigation into the influence of phytotherapy on the size of macroprolactinomas. In patients responsive to this kind of treatment, tumour regression was witnessed within 6 months of herbal remedy use. A substantial tumour downsizing was accompanied by vision restitution;namely, in a number of cases, sight impairments are the first indicators of tumour presence. The basic parameters used for phytotherapeutic efficiency estimation and follow-up were the size of the tumour and the state of the field-of-vision, established both prior to and following phytotherapy. The results of the study presented herein unequivocally demonstrated the efficiency of phytotherapy in macroprolactinoma tumour mass downsizing, providing therefore solid grounds for the implementation of phytotherapy as a novel treatment modality of this tumour cluster.

摘要

该研究旨在证明植物疗法在缩小大泌乳素瘤方面的有效性。对植物疗法(PT)有效性的比较基于患者在开始PT治疗之前提交的病历,这些病历表明了基于患部核磁共振成像(NMRI)和/或计算机断层扫描(CT)结果所确立的诊断,并提供了视野检查结果和激素状态测定结果。对参考文献中文件的深入研究提供了有关肿瘤大小和催乳素水平的信息。将参考文献中的数据与植物疗法完成后提交的病历进行比较。本研究给出了一项为期五年的关于植物疗法对大泌乳素瘤大小影响的调查结果。在对这种治疗有反应的患者中,在使用草药治疗的6个月内观察到肿瘤缩小。肿瘤显著缩小伴随着视力恢复;也就是说,在许多情况下,视力障碍是肿瘤存在的首要指标。用于评估植物疗法有效性和后续跟踪的基本参数是植物疗法前后所确定的肿瘤大小和视野状况。本文所呈现的研究结果明确证明了植物疗法在缩小大泌乳素瘤肿瘤体积方面的有效性,因此为将植物疗法作为这一肿瘤群的一种新型治疗方式的实施提供了坚实依据。